Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease
T. Christian H. Mix, Robert M. Brenner, Mark E. Cooper, Dick De Zeeuw, Peter Ivanovich, Andrew S. Levey, Janet B. McGill, John J.V. McMurray, Patrick S. Parfrey, Hans Henrik Parving, Brian J.G. Pereira, Giuseppe Remuzzi, Ajay K. Singh, Scott D. Solomon, Catherine Stehman-Breen, Robert D. Toto, Marc A. Pfeffer*
Dive into the research topics of 'Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease'. Together they form a unique fingerprint.